Inhibition of tumor metastasis by sodium caffeate and its effect on angiogenesis

Feng Xu1, Danqing Song, Yongsu Zhen

  • 1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing. andrewfxu@sina.com.cn

Oncology
|October 2, 2004
PubMed
Abstract

Insights

Sodium caffeate (SC) demonstrated significant antimetastatic and antiangiogenic effects. This compound effectively inhibited tumor metastasis and angiogenesis in preclinical models, showing promise as a therapeutic agent.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Metastasis and tumor angiogenesis are critical processes in cancer progression.
  • Developing effective antimetastatic and antiangiogenic agents is a major goal in cancer therapy.

Purpose of the Study:

  • To synthesize and evaluate the antimetastatic and antiangiogenic potential of sodium caffeate (SC).
  • To investigate the in vitro and in vivo mechanisms of SC's action against tumor metastasis and angiogenesis.

Main Methods:

  • In vivo studies utilized the Lewis lung carcinoma pulmonary metastasis model and the chicken chorioallantoic membrane (CAM) model.
  • In vitro assays included MTT for proliferation, flow cytometry for apoptosis, cell attachment, cell invasion, and zymography for gelatinase secretion.
  • Human umbilical vein endothelial cells (ECV304) and human high metastatic giant cell carcinoma of the lung (PG) cells were used for in vitro experiments.

Main Results:

  • SC significantly inhibited pulmonary metastasis by 55% and CAM angiogenesis by 70% in vivo.
  • In vitro, SC induced apoptosis in ECV304 cells, inhibiting proliferation.
  • SC reduced the adhesion and invasion of PG cells and inhibited MMP-2 and MMP-9 secretion.

Conclusions:

  • Sodium caffeate (SC) exhibits potent antimetastatic properties.
  • SC possesses significant antiangiogenic activity, suggesting its potential as a dual-action cancer therapeutic.

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...